BPaL Patent Rejection: TB Treatment Access, Generic Competition and Innovation

What the patent rejection changes

The rejected application was filed by the US-based Global Alliance for TB Drug Development, known as TB Alliance, for the combination of bedaquiline, pretomanid and linezolid. The applicant cannot use this particular application to claim exclusive patent rights over the combination in India.

The decision followed separate pre-grant oppositions by Eldred Tellis and Ganesh Acharya, and by the Delhi Network of Positive People, with support from access-to-medicines organisations. It illustrates how patient groups can scrutinise pharmaceutical patent applications before exclusive rights are granted.

The immediate effect is legal rather than clinical: a potential obstacle to competition has been removed. It is not a drug approval, a change in treatment guidelines or proof that prices have already fallen because of this decision.

• The source also reports earlier refusals of challenged bedaquiline-related applications, including the salt form and paediatric formulation.
• The rejection of one application should not be treated as a substitute for examining other applicable patents, licences and regulatory requirements.
• Manufacturing and export opportunities remain subject to relevant regulatory permissions and destination-country rules.

Why BPaL-based treatment matters

BPaL is a six-month, all-oral regimen recommended by WHO for eligible patients with drug-resistant TB. BPaLM adds moxifloxacin to the same three medicines. The source reports a treatment success rate of 89 per cent for BPaLM, compared with 52–75 per cent for standard regimens; these figures should not be presented as results for BPaL alone.

Shorter, oral treatment can reduce the burden associated with prolonged antibiotic courses and painful injections. It can also help patients resume work and family responsibilities, although clinical monitoring and adherence support remain essential.

India accounts for nearly a quarter of global TB cases, according to the source. More than 15,000 patients have already started BPaLM under the national programme, making equitable expansion to medically eligible patients a central implementation priority.

• Regimen selection must follow drug-resistance testing, clinical eligibility and programme treatment standards.
• A shorter course does not eliminate the need for monitoring adverse effects and treatment response.
• WHO recommendations do not imply that every TB patient should receive the same regimen.

Patentability safeguards: preventing evergreening without rejecting innovation

Under the Patents Act, an invention must satisfy requirements such as novelty, inventive step and industrial applicability, and must not fall within statutory exclusions. Section 25(1) permits any person to file a pre-grant opposition after publication of an application and before grant, on specified grounds.

Section 3(d) is relevant to debates on secondary pharmaceutical patents: a new form of a known substance must demonstrate enhanced efficacy to avoid the exclusion. For medicines, the Supreme Court’s Novartis ruling interprets efficacy as therapeutic efficacy. Section 3(e) excludes a mere admixture resulting only in the aggregation of the properties of its components.

These provisions are relevant analytical safeguards, but the supplied report does not reproduce the Patent Office’s detailed reasoning. It would therefore be incorrect to assert that this application was rejected specifically under either provision. A combination or improved formulation is not automatically unpatentable merely because it uses known medicines.

• Evergreening refers to attempts to prolong exclusivity through additional patents on changes to existing medicines without commensurate innovation.
• Secondary patents must be assessed claim by claim; they are not inherently invalid.
• The objective is to reward qualifying innovation while preventing unjustified restrictions on competition.
• The TRIPS framework and the Doha Declaration recognise the importance of protecting public health and promoting access to medicines.

Affordability depends on procurement, not patent status alone

Patients receiving drug-resistant TB treatment through the public health system already obtain their medicines free of cost. Consequently, lower procurement prices would initially benefit the government purchaser, potentially allowing a given budget to support more treatment courses.

The source quotes an access advocate reporting that a six-month BPaLM course costs $284, down from $588 in 2022, and links earlier price reductions to generic competition following the bedaquiline salt patent rejection. This price movement must not be attributed to the present combination-patent decision.

Patent rejection creates an opportunity, not a guaranteed price reduction. Actual gains depend on supplier entry, manufacturing capacity, quality assurance, tender design and uninterrupted delivery. Patients may still face travel expenses, nutritional needs, investigations outside the programme and lost income.

• Track actual procurement prices before estimating savings attributable to the latest ruling.
• Use competition to improve supply resilience as well as affordability.
• Distinguish free medicines from genuinely affordable completion of treatment.

Patent rights and medicine regulation are separate

The Patent Office determines whether an applicant can obtain exclusive rights over an invention. CDSCO and the applicable drug regulatory framework determine whether medicines may be marketed and used under specified conditions. The source states that bedaquiline and pretomanid have been approved for use under NTEP.

WHO prequalification assesses whether a medicine meets international standards of quality, safety and efficacy; it does not replace permissions required from Indian regulators. Expanding access therefore requires alignment between legal freedom to compete, regulatory compliance and national treatment standards.

• Patent rejection does not authorise unrestricted sale or clinical use.
• Eligible patients require timely diagnosis, resistance testing and linkage to treatment.
• Quality-assured procurement and pharmacovigilance must accompany treatment expansion.